Payment overview · 2025
General Payments
$555.55
14 reported records · 8 companies
Healthcare provider profile · identity verified
Sanjit K Dutta, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · SPOKANE, WA · NPI 1881610038
Verified facts
What the public records show
CMS Open Payments records show Sanjit K Dutta, MD received $555.55 in general payments during 2025 across 14 reported records.
Novo Nordisk Inc accounted for 47.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Xifaxan.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $266.03 | 47.9% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $93.22 | 16.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $80.00 | 14.4% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $41.91 | 7.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.00 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.21 | 4.2% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.13 | 3.4% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.05 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $555.55 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $150.20 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $93.22 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $41.91 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $30.48 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $25.20 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $24.00 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 201 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
201 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
129 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
18 | 18 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1303 | 357 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 595 | 107 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 561 | 139 |
| Losartan Potassium | Losartan Potassium | 464 | 124 |
| Lisinopril | Lisinopril | 460 | 126 |
| Trazodone Hcl | Trazodone Hcl | 437 | 89 |
| Gabapentin | Gabapentin | 418 | 83 |
| Omeprazole | Omeprazole | 415 | 114 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 406 | 119 |
| Tamsulosin Hcl | Tamsulosin Hcl | 341 | 92 |
| Potassium Chloride | Potassium Chloride | 320 | 88 |
| Metformin Hcl | Metformin Hcl | 279 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 275 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 272 | 72 |
| Citalopram Hbr | Citalopram Hydrobromide | 250 | 48 |
| Tramadol Hcl | Tramadol Hcl | 230 | 51 |
| Duloxetine Hcl | Duloxetine Hcl | 224 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 56 |
| Jardiance | Empagliflozin | 201 | 47 |
| Ozempic | Semaglutide | 201 | 38 |
| Metformin Hcl Er | Metformin Hcl | 200 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 185 | 47 |
| Furosemide | Furosemide | 175 | 48 |
| Prednisone | Prednisone | 170 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 50 |
| Bupropion Xl | Bupropion Hcl | 168 | 37 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 159 | 36 |
| Allopurinol | Allopurinol | 147 | 36 |
| Alendronate Sodium | Alendronate Sodium | 142 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 137 | 29 |
| Sertraline Hcl | Sertraline Hcl | 137 | 30 |
| Eliquis | Apixaban | 129 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 124 | 59 |
| Pregabalin | Pregabalin | 112 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 111 | 26 |
| Montelukast Sodium | Montelukast Sodium | 111 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 110 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 23 |
| Ondansetron Odt | Ondansetron | 99 | 34 |
| Xarelto | Rivaroxaban | 98 | 26 |
| Meloxicam | Meloxicam | 95 | 37 |
| Lorazepam | Lorazepam | 94 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 94 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 21 |
| Methocarbamol | Methocarbamol | 88 | 24 |
| Spironolactone | Spironolactone | 84 | 27 |
| Ezetimibe | Ezetimibe | 82 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 13 |
| Clonidine Hcl | Clonidine Hcl | 77 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | suppressed |
| Simvastatin | Simvastatin | 75 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 73 | 18 |
| Carvedilol | Carvedilol | 70 | 19 |
| Chlorthalidone | Chlorthalidone | 70 | 24 |
| Clonazepam | Clonazepam | 70 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 70 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 69 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 67 | 39 |
| Buspirone Hcl | Buspirone Hcl | 66 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 21 |
| Fenofibrate | Fenofibrate Nanocrystallized | 61 | 17 |
| Synthroid | Levothyroxine Sodium | 61 | 18 |
| Mirtazapine | Mirtazapine | 60 | 14 |
| Donepezil Hcl | Donepezil Hcl | 58 | 17 |
| Famotidine | Famotidine | 57 | 17 |
| Finasteride | Finasteride | 56 | 20 |
| Alprazolam | Alprazolam | 55 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 55 | 14 |
| Cephalexin | Cephalexin | 50 | 28 |
| Torsemide | Torsemide | 49 | 14 |
| Azithromycin | Azithromycin | 47 | 38 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 46 | 14 |
| Ipratropium Bromide | Ipratropium Bromide | 45 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 45 | suppressed |
| Baclofen | Baclofen | 44 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 44 | 14 |
| Amoxicillin | Amoxicillin | 43 | 23 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 39 |
| Memantine Hcl | Memantine Hcl | 41 | suppressed |
| Cefdinir | Cefdinir | 39 | 26 |
| Topiramate | Topiramate | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 11 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Levetiracetam | Levetiracetam | 38 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 30 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 32 |
| Estradiol | Estradiol | 34 | 15 |
| Prolia | Denosumab | 34 | 21 |
| Ventolin Hfa | Albuterol Sulfate | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 26 |
| Valacyclovir | Valacyclovir Hcl | 33 | 21 |
| Atenolol | Atenolol | 31 | suppressed |
| Irbesartan | Irbesartan | 31 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Lactulose | Lactulose | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Risperidone | Risperidone | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Digoxin | Digoxin | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Lidocaine | Lidocaine | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Modafinil | Modafinil | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Folic Acid | Folic Acid | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Mupirocin | Mupirocin | 19 | 16 |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Dulera | Mometasone/Formoterol | 18 | suppressed |
| Epinephrine | Epinephrine | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 18 | 18 |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Methimazole | Methimazole | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 14 | suppressed |
| Budesonide Dr | Budesonide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 13 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 13 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Lyrica | Pregabalin | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Verapamil Sr | Verapamil Hcl | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $555.55 · 14 records | Novo Nordisk Inc | ABRYSVO, Dexcom G6 Transmitter, GEMTESA, MOUNJARO, Ozempic, PREVNAR 20, REXULTI, Rybelsus, VOQUEZNA, Wegovy, XIFAXAN, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error